Trial Profile
An Open-labelled, Randomised, Parallel Group, 3 Week run-in and 24 Week Treat-to-target Comparison of Biphasic Insulin Aspart 30 Once Daily Versus Insulin Glargine Once Daily Both in Combination With Metformin and Glimepiride in Chinese and Japanese Insulin Naive Subjects With Type 2 Diabetes.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary) ; Insulin glargine (Primary) ; Glimepiride; Metformin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EasyMix
- Sponsors Novo Nordisk
- 06 Jul 2012 Actual patients number is 521 as reported by ClinicalTrials.gov (Parent trial: NCT01123980).
- 06 Jul 2012 Actual patients number is 521 as reported by ClinicalTrials.gov (Parent trial: NCT01123980).
- 15 Jun 2012 Actual initiation date changed from Feb 2011 to Jan 2011 as reported by ClinicalTrials.gov.